A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies
Authors:
- Alexandra KatzAKAlexandra Katz
- Aidan ShulkinASAidan Shulkin
- Asmaa HousniAHAsmaa Housni
- Amélie Roy‐FlemingARAmélie Roy‐Fleming
- Rémi Rabasa‐LhoretRRRémi Rabasa‐Lhoret
- Jean‐Francois YaleJYJean‐Francois Yale
- Michael A. TsoukasMTMichael A. Tsoukas
- Tricia M. PetersTPTricia M. Peters
- Anne‐Sophie BrazeauABAnne‐Sophie Brazeau
Open Access
- 12 January 2026
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 2594-2614
Abstract
Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear. Our aim is to synthesise the evidence on the glycaemic effects of GCs in PWT1D across various formulations, doses and administration routes, and to outline management strategies. In August 2025, a systematic search of MEDLINE, Embase and CENTRAL was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta‐Analysis guidelines. Eligible studies included adult PWT1D exposed to GCs and reported glycaemic outcomes and/or management strategies. Twenty‐two studies were included, comprising 368 PWT1D. GC exposure was consistently associated with marked hyperglycaemia and increased insulin requirements. Oral and intravenous GC regimens required substantial insulin dose escalation, in many cases up to 70% from baseline. During pregnancy, antenatal corticosteroids were best managed with structured subcutaneous or intravenous insulin protocols. Local injectable GCs caused delayed but prolonged excursions and required careful blood glucose (BG) monitoring. Emerging data suggest that automated‐insulin delivery (AID) systems attenuate BG elevation but still require user intervention. Thus, GC therapy in PWT1D destabilises glycaemic management, though impact and timing vary by formulation, dose, administration route, patient‐specific factors and clinical context. Proactive, individualised insulin adjustments aligned with GC pharmacokinetics and frequent BG monitoring or continuous glucose monitor use represent the most practical current strategy. Further research is required to develop evidence‐based guidelines and to clarify the role of AID.Keywords
This publication has 65 references indexed in Scilit:
- Managing Hyperglycaemia During Antenatal Corticosteroid Administration in a Pregnant Woman with Type 1 Diabetes Using an Advanced Hybrid Closed-Loop System: Case ReportSN Comprehensive Clinical Medicine, 2025
- Pharmacokinetics and Pharmacodynamics of Systemic Corticosteroids in Autoimmune and Inflammatory Diseases: A Review of Current EvidenceClinical Pharmacokinetics, 2024
- Practical Guide to Glucocorticoid Induced Hyperglycaemia and DiabetesDiabetes Therapy, 2023
- Challenging steroid-induced worsening of hyperglycaemia in type 1 diabetes with advanced hybrid closed-loop systemsActa Diabetologica, 2021
- Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative ReviewDiabetes Therapy, 2020
- Co-Managing Patients with Type 1 Diabetes and CancerCurrent Diabetes Reports, 2016
- Regulation of Glucose Homeostasis by Glucocorticoids2015
- Hyperglycemia in Hospitalized Patients Receiving Corticosteroid Premedication before the Administration of Radiologic Contrast MediumAcademic Radiology, 2011
- Beyond Comorbidity Counts: How Do Comorbidity Type and Severity Influence Diabetes Patients’ Treatment Priorities and Self-Management?Journal of General Internal Medicine, 2007
- Choice and dose of corticosteroid for antenatal treatmentsAmerican Journal of Obstetrics and Gynecology, 2004